HCPCS Level II code J1551 denotes an injection of immune globulin (Cutaquig), billed per 100 mg unit. This biologic drug code is important nationally because immune globulin products are used for primary and secondary immunodeficiency, autoimmune conditions, and other indications where immunomodulation or passive immunity is required. Accurate coding of J1551 affects claims processing, drug utilization reporting, and patient cost sharing for a high-cost injectable therapy.

Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise discussion of clinical context and typical sites of service, along with what to expect in payer coverage approaches and common billing considerations. The publication also outlines benchmarks and policy-related observations relevant to procurement, coding consistency, and site-of-care implications for injectable immune globulin products.

This summary is intended for billing managers, revenue cycle staff, clinicians involved in infusion services, and policy analysts seeking a national perspective on coding and payment considerations for immune globulin therapies represented by J1551.